Fig. 3. Effect of RAS inhibition on tumor growth.

Mice bearing DA3-xenograft mammary tumors were fed and treated as described in Materials and Methods. Tumors were measured by ultrasound, and their average growth at the end of the 3-week period of the experiment is presented as a bar chart. Compared to baseline, vehicle-treated tumors grew 17.8-fold (n = 7) on average, while tumors treated at the indicated periods with low-dose or high dose FTS grew 15.8-fold (n = 7) and 7.7-fold (n = 5), respectively. Compared to the average tumor size in the control group, tumor size after 3 weeks in the low-dose and high-dose FTS-treated groups were 88.6% (not significant) and 50.7% (P = 0.019), respectively.